FOLFOX6 Combination as the FirstLine （FOLFOX6组合得力）.pdfVIP

ORIGINAL ARTICLE FOLFOX-6 Combination as the First-Line Treatment of Locally Advanced and/or Metastatic Pancreatic Cancer Marwan Ghosn, MD,* Fadi Farhat, MD,† Joseph Kattan, MD,* Fariha Younes, Pharm D,* Walid Moukadem, MD,‡ Fadi Nasr, MD,* and Georges Chahine, MD* Key Words: pancreatic carcinoma, first-line, oxaliplatin, 5-FU, Objective: Advanced pancreatic carcinoma (APC) has a poor prog- leucovorin, FOLFOX-6 nosis and chemotherapy remains the most common approach. Gem- citabine was the only drug recently approved for use as single agent (Am J Clin Oncol 2007;30: 15–20) therapy in APC. However, the combination of oxaliplatin and 5-fluorouracil (5-FU) has shown some promising results. This phase II trial was conducted to investigate the efficacy of oxaliplatin, 5-FU, and folinic acid (FOLFOX-6) in previously untreated APC ancer of the pancreas continues to be a serious health patients. Cproblem with approximately 227,000 deaths per year in Methods: We studied response rate, time to progression, and tox- the world mainly because of late presentation. Ninety percent icity profile. Treatment included oxaliplatin 100 mg/m2 and folinic of cases approximately are diagnosed with advanced pancre- acid 400 mg/m2 on day 1 followed by a 5-FU bolus 400 mg/m2 and atic carcinoma at the time of diagnosis. Deaths are associated a 46-hour infusion of 3000 mg/m2 every 2 weeks. with the aggressiveness of pancreatic cancers, and also with Results: From January 2003 through December 2004, 30 eligible